Â
Sponsored by
NATIONAL NEWS
FDA halts Amgen study after teen patient death
Posted: Feb 26, 2013 12:26 PM by Associated Press
WASHINGTON (AP) - Federal health regulators say they have halted Amgen's studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial.
The Food and Drug Administration says it is gathering information about the death, but has shut down all studies of the drug in children.
Sensipar is approved for adults to treat over-activity of the parathyroid gland. Amgen Inc. had been studying the drug to see whether it works in children.
The FDA says in a statement it is unclear whether Amgen's drug had a role in the patient's death, but it is reminding doctors to prescribe it carefully.
The agency says doctors should monitor patients' calcium levels to make sure they don't fall to dangerous levels.
PLEASE HELP US MODERATE COMMENTS
Offensive or inappropriate comments are subject to removal. To report a comment, please e-mail us at feedback@ksby.com, and include the name of the story and information on the comment.
Thank you! KSBY.com
KSBY.com is social!
KSBY.COM VIDEOS
-
Military widow finds another woman's name engraved on her husband's tombstone
Views: 271 June 18, 2013 -
Mother taken into custody after driving under the influence with her son in the car
Views: 43 June 18, 2013 -
Middle schoolers get opportunity to play paintball with local law enforcement
Views: 12 June 16, 2013
Comments